<DOC>
	<DOCNO>NCT01308944</DOCNO>
	<brief_summary>This research look effect biobehavioral factor stress whether factor alter body responds chemotherapy , one purpose study determine addition beta-blocker Propranolol ( Inderal ) tolerable give chemotherapy treatment newly diagnose ovarian , fallopian tube , primary peritoneal cancer . An additional purpose study understand behavioral factor depression anxiety alter different blood marker affect tumor vascularity . The Investigator wish determine whether use beta-blocker drug Inderal , might alter behavioral factor draw blood prior administration Inderal well give behavioral questionaires different time point . Beta-blockers commonly use treatment hypertension , protection heart heart attack , irregularity heartbeat . Altering factor might boost immune system affect area cancer biology , thereby allow chemotherapy effective . The significance research may help improve treatment disease future .</brief_summary>
	<brief_title>Therapeutic Targeting Stress Factors Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Preoperative Eligibility Criteria : Inclusion Criteria Suspected preoperative diagnosis invasive ovarian cancer , primary peritoneal carcinoma , fallopian tube cancer base image CA125 level Patients must schedule planned tumor debulking least 72 hour advance order patient take least 48 hour prescribe Propranolol Intention chemotherapy administration Washington University An approve informed consent authorization permit release personal health information must sign patient guardian Age ≥ 18 year Gynecologic Oncology Group performance status 02 Patient 's childbearing age must negative pregnancy test Exclusion Criteria Patients receive neoadjuvant chemotherapy ovarian , primary peritoneal , fallopian tube cancer exclude . Patients prior diagnosis borderline tumor surgically resect subsequently develop unrelated new invasive epithelial ovarian , primary peritoneal , fallopian tube cancer eligible , provide receive chemotherapy tumor Patients receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation therapy localize cancer breast , head neck , skin permit provide complete 3 year prior registration , patient remain free recurrent metastatic disease Patients past history primary endometrial cancer exclude unless follow condition meet : stage great stage IA ; superficial myometrial invasion , without vascular lymphatic invasion ; poorly differentiate subtypes , include papillary serous , clear cell , FIGO grade 3 lesion . With exception nonmelanoma skin cancer specific malignancy note , patient invasive malignancy ( ) evidence cancer present last five year whose previous cancer treatment contraindicate protocol therapy exclude . Use systemic glucocorticoid Prednisone Decadron last month Inability accurately answer question ( e.g . dementia , brain metastasis ) speak English Cirrhosis liver Patients GOG Performance status 3 4 Patients age 18 Comorbid condition : Addison 's disease , autoimmune hepatitis , hepatitis B , hepatitis C , AIDS HIV , lupus erythematosus , mixed connective tissue disease , rheumatoid arthritis Any patient already betablockers contraindicate receive betablockers Postoperative Eligibility Criteria : Inclusion Criteria Histologic diagnosis invasive epithelial ovarian cancer , primary peritoneal carcinoma , fallopian tube cancer . Histologic epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell carcinoma , mixed epithelial carcinoma , adenocarcinoma otherwise specify . However , histologic feature must compatible primary Müllerian epithelial adenocarcinoma . Patients low grade invasive epithelial ovarian cancer may participate . Stages IIV cancer Patients undergone suboptimal optimal tumor debulking Gynecologic Oncology Group performance status 02 Patients must adequate : 1 . Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1500/ml . 2 . Platelets great 100,000/ml 3 . Renal function : Creatinine ≤ 1.5 x institutional upper limit normal 4 . Hepatic function : Bilirubin le equal 1.5 x institutional upper limit normal ; SGOT alkaline phosphatase less equal 2.5 x institutional upper limit normal . 5 . Neurologic function : Neuropathy ( sensory motor ) less equal grade 1 accord Common Toxicity Criteria Adverse Events version 3 ( CTCAE ) . 6 . Blood coagulation parameter : PT international normalize ratio ( INR ) ≤1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin management venous thrombosis include pulmonary embolus ) PTT &lt; 1.2 time institutional upper limit normal . Exclusion Criteria Patients receive targeted therapy ( include limit vaccine , antibody , tyrosine kinase inhibitor ) hormonal therapy management primary peritoneal , ovarian , fallopian tube cancer . Patients receive concurrent bevacizumab target therapy part primary chemotherapy . Patients nonepithelial ovarian tumor require adjuvant chemotherapy , borderline epithelial ovarian tumor , recurrent invasive epithelial ovarian , low grade ovarian cancer , primary peritoneal , fallopian tube cancer treat surgery ( patient stage IA IB ) Patients synchronous primary endometrial cancer exclude unless follow condition meet : stage great stage IA ; superficial myometrial invasion , without vascular lymphatic invasion ; poorly differentiate subtypes , include papillary serous , clear cell , FIGO grade 3 lesion Metastases ovary organs except fallopian tube primary peritoneal carcinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>invasive epithelial ovarian cancer ,</keyword>
	<keyword>primary peritoneal carcinoma ,</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>